Literature DB >> 8141217

A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry.

L A Barbour1, S D Kick, J F Steiner, M E LoVerde, L N Heddleston, J L Lear, A E Barón, P L Barton.   

Abstract

OBJECTIVE: Our purpose was to evaluate the subclinical occurrence of heparin-induced osteoporosis in pregnancy, by means of bone densitometry. STUDY
DESIGN: A prospective, consecutive cohort of 14 pregnant women requiring heparin therapy and 14 pregnant controls matched for age, race, and smoking status was identified by 20 weeks' gestation at a university medical center. Proximal femur bone density measurements were taken at baseline, immediately post partum, and 6 months post partum in the cases and controls. Vertebral measurements were also obtained on both groups immediately post partum and 6 months post partum. Bone density as a function of heparin dosing and duration was examined. Nonparametric statistical tests were used for all comparisons.
RESULTS: Five of 14 cases (36%) had a > or = 10% decrease from the baseline proximal femur measurements to immediate postpartum values versus none of the 14 matched controls (p = 0.04). Mean proximal femur bone density measurements also decreased in the cases (p = 0.01); this difference continued to be statistically significant 6 months post partum (p = 0.03). No dose-response relationship could be demonstrated.
CONCLUSION: Heparin adversely affected bone density in about one third of exposed patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8141217     DOI: 10.1016/s0002-9378(94)70299-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

Review 1.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Proteoglycans and osteolysis.

Authors:  Marc Baud'Huin; Céline Charrier; Gwenola Bougras; Régis Brion; Frédéric Lezot; Marc Padrines; Dominique Heymann
Journal:  Methods Mol Biol       Date:  2012

3.  Maternal plasma osteoprotegerin concentration in normal pregnancy.

Authors:  Joon-Seok Hong; Joaquin Santolaya-Forgas; Roberto Romero; Jimmy Espinoza; Luís F Gonçalves; Yeon Mee Kim; Samuel Edwin; Bo Hyun Yoon; Jyh Kae Nien; Sonia Hassan; Moshe Mazor
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

4.  [Heart diseases in pregnancy].

Authors:  Vera Regitz-Zagrosek; Christa Gohlke-Bärwolf; Annette Geibel-Zehender; Markus Haass; Harald Kaemmerer; Irmtraut Kruck; Christoph Nienaber
Journal:  Clin Res Cardiol       Date:  2008-09       Impact factor: 5.460

Review 5.  Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin.

Authors:  S A Dobie; A J Ellsworth; M L Linenberger
Journal:  West J Med       Date:  1996-04

Review 6.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

Review 7.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

Review 8.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

Review 9.  Antithrombotic therapy for prosthetic valves: routine treatment and special considerations.

Authors:  A M Al-Ahmad; D Hartnett-Daudelin; D N Salem
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

10.  Post-partum sacral fracture associated with heparin treatment.

Authors:  Vincent Goëb; Victor Strotz; Mathieu Verdet; Xavier Le Loët; Olivier Vittecoq
Journal:  Clin Rheumatol       Date:  2008-05-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.